Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Akira Sawaki
Efficacy and Safety of TAS-116, an Oral Inhibitor of Heat Shock Protein 90, in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumour Refractory to Imatinib, Sunitinib and Regorafenib: A Phase II, Single-Arm Trial
European Journal of Cancer
Cancer Research
Oncology
Regorafenib for Advanced Gastrointestinal Stromal Tumors Following Imatinib and Sunitinib Treatment: A Subgroup Analysis Evaluating Japanese Patients in the Phase III GRID Trial
International Journal of Clinical Oncology
Medicine
Surgery
Oncology
Hematology
Related publications
Phase II Trial of Imatinib in Metastatic or Unresectable Gastrointestinal Stromal Tumors,NEMROCK Experience.
Research in Oncology
Phase II Trial of Continuous Regorafenib Dosing in Patients With Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib
Oncologist
Cancer Research
Medicine
Oncology
Safety and Efficacy of Regorafenib in Patients With Treatment-Refractory Metastatic Colorectal Cancer in Turkey: The Single-Arm, Open-Label REGARD Study
BMJ Open
Medicine
Imatinib for the Treatment of Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumours: Systematic Review and Economic Evaluation
Health Technology Assessment
Medicine
Health Policy
Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–resistant Patients: Recommendations and Evidence
Current Oncology
Oncology
Comparison of Performance of Various Tumour Response Criteria in Assessment of Regorafenib Activity in Advanced Gastrointestinal Stromal Tumours After Failure of Imatinib and Sunitinib
European Journal of Cancer
Cancer Research
Oncology
A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors
Molecular Cancer Therapeutics
Cancer Research
Oncology
